Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

EACS 2017: Up to a Quarter of HIV-Negative Gay Men Attending 3 English Clinics Used PrEP in the Last Year

A prospective cohort study of gay men attending 3 clinics in southern England --56 Dean Street and Mortimer Market Centre in London and the Brighton & Hove SHAC (Sexual Health & Contraception) service -- have found that 23% of HIV-negative service users who responded to a follow-up questionnaire had used PrEP (pre-exposure prophylaxis) in the last year. These interim results from the AURAH2 study were presented recently at the 16th European AIDS Conference (EACS 2017) in Milan.

alt

Read more:

EACS 2017: Survey of Dating App Users Finds that PrEP Usage Has Not Increased in Europe in the Last Year

A study of men who have sex with men (MSM) conducted by the European Centre for Disease Prevention and Control (ECDC) in collaboration with the gay contact site Hornet has found that pre-exposure prophylaxis (PrEP) usage has not increased, on average, among its respondents over the proportion reported last year, when a similar survey was carried out. The results were presented recently at the 16th European AIDS Conference (EACS 2017) in Milan.

alt

Read more:

IAS 2017: Experts Agree that Intermittent Oral PrEP Probably Won't Work for Women

Two presenters at the recent International AIDS Society Conference on HIV Science (IAS 2017) in Paris told delegates that both trial results and analysis of drug levels support the idea that event-related or "on demand" pre-exposure prophylaxis (PrEP) might not be sufficiently powerful to prevent HIV infection in women and trans men via vaginal sex.

alt

Read more:

No New HIV Infections Among Kaiser PrEP Users, But Cascade Shows Missed Opportunities

No new HIV infections have occurred among nearly 5000 people who started Truvada for pre-exposure prophylaxis (PrEP) in the Kaiser Permanente Northern California health system, according to a letter in the July 29 edition of Clinical Infectious Diseases.

alt

Read more:

IAS 2017: PrEP Use in U.S. Exceeds 100,000 in Gilead Pharmacy Survey

An estimated 120,000 people in the U.S. have started Truvada (tenofovir/emtricitabine) for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of retail and mail-order pharmacies by Gilead Sciences, presented at the recent 9th IAS Conference on HIV Science (IAS 2017) in Paris.

alt

Read more: